Preview

General Reanimatology

Advanced search

Oxidative Stress and Hepatic Monooxygenase Function in Coronary Heart Disease Patients with Multiple Organ Dysfunction

https://doi.org/10.15360/1813-9779-2008-4-32

Abstract

Objective: to study hepatic monooxygenase function (HMF) in cardiosurgical patients with multiple organ dysfunction (MOD). Subjects and methods. Twenty-six patients with MOD signs after operations on the open heart and 29 patients with an uncomplicated postoperative period were examined. The severity of HMF was evaluated by the SOFA scale and HMF was assessed by the pharmacokinetics of antipyrine (AP). Results. Within the first 24 hours after surgery, there were significant signs of MOD and a nearly two-fold reduction in HMF in the study group. A less significant depression of HMF was observed in the control group. On postoperative days 3—4, the total index of MOD noticeably decreased in the study group. There was an increase in HMF in both groups. On days 10—12 after surgery, the severity of MOD distinctly increased in the study group, which was accompanied by a considerable reduction in HMF. In this period, in the control group HMF corresponded to the baseline values. Correlation analysis revealed a direct relationship of the total index of MOD severity with AP Tj/2 and a negative correlation of the number of organ lesions with AP clearance. Conclusion. In cardiosurgical patients, MOD causes a more significant and longer diminution of HMF than in those with an uncomplicated postoperative period. The rate of HMF reduction is directly related to the number of organ lesions and the total index of MOD severity. Key words: hepatic monooxygenase function, multiple organ dysfunction, antipyrine, cardiosurgical patients.

References

1. Караськов А. М., Ломиворотов В. В.

2. Скопец А. А.Метаболические сдвиги у больных приобретенными пороками сердца, оперированных в условиях гипотермической и нормотермической перфузии: автореф. дис. .канд. мед. наук. Новосибирск; 2004.

3. Трубицина Е. С.Применение антиоксиданта мексидола у больных ишемической болезнью сердца, оперированных в условиях искусственного кровообращения: автореф. дис. .канд. мед. наук. Новосибирск; 2006.

4. Gottlieb R. A.Cytochrome P450: major player in reperfusion injury. Arch. Biochem. Biophys. 2003; 420 (2): 262—267.

5. El-Kadi A., Bleau A., Dumont I. et al.Role of reactive oxygen intermediates in the decrease of hepatic cytochrome P450 activity by serum of humans and rabbits with an acute inflammatory reaction. Drug Metab. Dispos. 2000; 28 (9): 1112—1120.

6. Harbrecht B., Frye R., Zenati M.Cytochrome P-450 activity is differentially altered in severely injured patients. Crit. Care Med. 2005; 33 (3): 541—54

7. Lee S. H., Lee S. M.Suppresion of hepatic cytochrome P450-mediated drug metabolism during the late stage of sepsis in rats. Shock 2005; 23 (2): 144—149.

8. Carcillo J., Dougty L., Kofos D. et al.Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intens. Care Med. 2003; 29 (6): 980—984.

9. Murrau M., Petrovic N.Cytochromes P450: decision-making tools for personalized therapeutics. Curr. Opin. Mol. Ther. 2006; 8 (6): P. 480—486.

10. Nebert D., Russell D.Clinical importance of the cytochromes P450. Lancet 2002; 360 (9340): 1155—1162.

11. Motoyama T., Okamoto K., Kukita I. et al.Possible role of increased oxi-dant stress in multiple organ failure after systemic inflammatory response syndrome. Crit. Care Med. 2003; 31 (4): 1048—1052.

12. VincentJ.Organ dysfunction as an outcome measure: The SOFA Score. Sepsis 1997; 1 (1): 53—54.

13. Shrarer J., Wrighton S.Identification of the human hepatic cytochromes P-450 involved in the in vitro oxidation of antipyrine. Drug Metab. Dispos. 1996; 24 (4): 487—494.

14. Tanaka E., Breimer D. In vivofunction tests of hepatic drug-oxidizing capacity in patients with liver disease. T. Clin. Pharm. Ther. 1997; 22 (4): 237—249.

15. Неделькина С. В., Дианова И. И., Субботина Р. С., Салганик Р. И.Непрямой метод определения активности ферментов, метаболизиру-ющих лекарственные вещества и его применение в клинике. Вопр. мед. химии 1977; 6: 844—847.

16. Zuber R., Anzenbacherova E., Anzenbacher P.Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 2002; 6 (2): 189—198.


Review

For citations:


Nepomnyashchikh V.A., Lomivorotov V.V., Deryagin M.N., Lomivorotov V.N., Knyazkova L.G., Yefimov A.A. Oxidative Stress and Hepatic Monooxygenase Function in Coronary Heart Disease Patients with Multiple Organ Dysfunction . General Reanimatology. 2008;4(4):32. (In Russ.) https://doi.org/10.15360/1813-9779-2008-4-32

Views: 1069


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1813-9779 (Print)
ISSN 2411-7110 (Online)